Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARES: Adjuvant Apalutamide + ADT for High-Risk Prostate Cancer Post-Prostatectomy
NCT05778097Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2023
- Primary completion
- Aug 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by Nanjing Drum-Tower Hospital. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05778097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05778097.